894 related articles for article (PubMed ID: 17156669)
41. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
[TBL] [Abstract][Full Text] [Related]
42. Etanercept: new indication. For ankylosing spondylitis: another option.
Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
[TBL] [Abstract][Full Text] [Related]
43. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.
Mathieu S; Joly H; Baron G; Tournadre A; Dubost JJ; Ristori JM; Lusson JR; Soubrier M
Rheumatology (Oxford); 2008 Aug; 47(8):1203-7. PubMed ID: 18524805
[TBL] [Abstract][Full Text] [Related]
44. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
Davis JC; Van der Heijde DM; Dougados M; Braun J; Cush JJ; Clegg DO; Inman RD; de Vries T; Tsuji WH
J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
[TBL] [Abstract][Full Text] [Related]
45. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
[TBL] [Abstract][Full Text] [Related]
46. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis.
Bes C; Yazici A; Soy M
Rheumatol Int; 2013 Jun; 33(6):1415-8. PubMed ID: 23143665
[TBL] [Abstract][Full Text] [Related]
48. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
Wallenius M; Rødevand E; Skomsvoll JF
Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
[TBL] [Abstract][Full Text] [Related]
49. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
[TBL] [Abstract][Full Text] [Related]
50. Effects of tumor necrosis factor inhibitor on serum level of HLA-B27 and PDCD-1 in patients with ankylosing spondylitis.
Chen X; Zhou X; Li X; Tang J; Hu X; Wang J; Xu C
Cell Biochem Biophys; 2014 Nov; 70(2):1453-7. PubMed ID: 25005770
[TBL] [Abstract][Full Text] [Related]
51. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.
Maksymowych WP; Rahman P; Shojania K; Olszynski WP; Thomson GT; Ballal S; Wong RL; Inman RD;
J Rheumatol; 2008 Oct; 35(10):2030-7. PubMed ID: 18785308
[TBL] [Abstract][Full Text] [Related]
52. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
Gorman JD; Sack KE; Davis JC
N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
[TBL] [Abstract][Full Text] [Related]
54. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab.
Braun J; van der Heijde D; Doyle MK; Han C; Deodhar A; Inman R; de Vlam K; Burmester GR; Van den Bosch F; Xu S; Visvanathan S; Rahman MU
Arthritis Rheum; 2009 Aug; 61(8):1032-6. PubMed ID: 19644896
[TBL] [Abstract][Full Text] [Related]
55. Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients.
Lin Z; Gu J; He P; Gao J; Zuo X; Ye Z; Shao F; Zhan F; Lin J; Li L; Wei Y; Xu M; Liao Z; Lin Q
Rheumatol Int; 2011 Feb; 31(2):233-8. PubMed ID: 20012866
[TBL] [Abstract][Full Text] [Related]
56. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
[TBL] [Abstract][Full Text] [Related]
57. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass.
Yazici S; Yazici M; Erer B; Erer B; Calik Y; Bulur S; Ozhan H; Ataoglu S
Platelets; 2010; 21(2):126-31. PubMed ID: 20050759
[TBL] [Abstract][Full Text] [Related]
58. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
[TBL] [Abstract][Full Text] [Related]
59. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
[TBL] [Abstract][Full Text] [Related]
60. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
